OR WAIT null SECS
At ACC 2023, HCPLive editorial team sat down with Clyde Yancy, MD, to learn more about his perspective on recent and upcoming advances in cardiovascular care. In this interview, Yancy discusses his perspective on the clinical trial data surrounding renal denervation as a treatment for hypertension.
The first major cardiology meeting of the calendar year, the American College of Cardiology (ACC) annual scientific sessions serves as a showcase for the latest advancements in cardiology—both those ready for real-world adoption and those years away from primetime.
A procedure and technology toeing that line at this year’s meeting is renal denervation. The subject of multiple posters and presentations, the discussion surrounding the potential treatment for hypertension has evolved with each passing meeting
In the week leading up to ACC 2023, a patient-level pooled analysis of data from the RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials added further perspectiveto conversations surrounding the real-world adoption of this treatment strategy.1 Using data from the 506 patients who underwent randomization in the trials, investigators determined the reduction in daytime ambulatory systolic blood pressure observed was significantly greater among patients receiving ultrasound renal denervation thanwith the sham procedure at 2 months, with a difference of 6 mmHg and this effect consistent across trials.
During their time on-site at ACC 2023, HCPLive sat down with Clyde Yancy, MD, chief of cardiology at Northwestern University Feinberg School of Medicine, to gain further perspective on the latest advances in the field. One of the authors of an accompanying editorial to this analysis published in JAMA Cardiology2, the HCPLive editorial team asked Yancy for further perspective on the prospect of renal denervation and whether or not the existing knowledge based surrounding use of this type of technology was ready for widespread adoption.
Yancy has no relevant disclosures.